Author: BusinessWire

SEATTLE–(BUSINESS WIRE)–#DemethylationAgents–According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forec…

TURKU, Finland–(BUSINESS WIRE)–Medicortex Finland Oy, a Finnish biotechnology company focusing on brain injury diagnostics and drug development, announces receiving funding from the Finnish government innovation funding branch Business Finland. The f…

NEW YORK–(BUSINESS WIRE)–Contentsquare, the leading experience analytics company, is partnering with leaders in the pharmaceutical and biotech sector to help manage the accelerated shift to digital healthcare.

As early as 2014, a McKinsey study foun…

AUXVASSE, Mo.–(BUSINESS WIRE)–#IND–Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology. In this role, Dr. Love will lead Sinclair’s Safety Pharmacology program and…

DUBLIN–(BUSINESS WIRE)–The “US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026” report has been added to ResearchAndMarkets.com’s offering.

The complete research report is divided into several sections focusing on the approaches foll…

RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised GSL Solutions, Inc. (GSL) on its sale to BD (Becton, Dickinson and Company), a leading global medical technology c…

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory ac…

Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide

Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio

Amgen to Host In…

Phase 1 clinical study report for Voriconazole Inhalation Powder indicated no treatment emergent adverse events at peak plasma levels for Invasive Pulmonary Aspergillosis

Phase 1 Single Ascending Dose study of Tacrolimus Inhalation Powder met and exc…

MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that…